Phathom Pharmaceuticals Inc (PHAT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $477.99M
Last updated: Nov 17, 2026 at 4:15 PM ET
Phathom Pharmaceuticals Inc (PHAT) Statistics
Phathom Pharmaceuticals (PHAT) has a market cap of $477.99M and an enterprise value of $458.98M. Revenue grew 86.75% over the last 12 months from the 12 months before. Its share count is up 15.66% from a year earlier.
Total Valuation
Enterprise value is 3.98% below the market cap, as cash exceeds debt.
| Market Cap | $477.99M |
|---|---|
| Enterprise Value | $458.98M |
| Latest price (Nov 17, 2026) | $5.50 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.7x. Its year-end P/S ranged from 6.9x to 686.6x from 2023 to 2025.
| P/S Ratio | 1.7x |
|---|---|
| Forward P/S | 1.5x |
Price Statistics
The stock is down 62.23% over 52 weeks and trades 19.35% below its 50-day average.
| Beta (1Y) | 0.97 |
|---|---|
| 52-Week Change | -62.23% |
| 1-Month Change | -21.54% |
| 3-Month Change | -40.99% |
| 6-Month Change | -51.75% |
| 5-Year Change | -75.61% |
| Total Return (1Y) | -62.23% |
| Total Return (3Y CAGR) | -9.82% |
| Total Return (5Y CAGR) | -23.41% |
| Return vs SPY (1Y) | -74.89% |
| Max Drawdown (1Y) | -71.90% |
| Max Drawdown (3Y) | -88.26% |
| Sharpe Ratio (1Y) | -1.41 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $6.82 |
| 200-Day Average | $9.95 |
| 52-Week Range | $5.01 to $18.31 |
| RSI (14 Days) | 39.6 |
| Average Volume (20 Days) | 1.89M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.76x current liabilities.
| Current Ratio | 1.76x |
|---|---|
| Quick Ratio | 1.72x |
| Interest Coverage | -0.42x |
Returns and Efficiency
Return on invested capital is 11.43% over the last 12 months, against a 5-year average of 55.24%.
| Return on Assets (ROA) | -24.06% |
|---|---|
| Return on Invested Capital (ROIC) | 11.43% |
| Return on Capital Employed (ROCE) | -15.48% |
| ROA (5Y Average) | -83.68% |
| ROIC (5Y Average) | 55.24% |
| Asset Turnover | 0.94x |
| Inventory Turnover | 6.92x |
| Receivables Turnover | 2.68x |
| Cash Conversion Cycle | 132 days |
Scores
PHAT has an Altman Z-Score of -4.86, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.86 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $274.88M over the last 12 months.
| Revenue | $274.88M |
|---|---|
| Revenue Growth (YoY) | +86.75% |
| Gross Profit | $221.78M |
| Operating Income | -$25.45M |
| Pretax Income | -$83.00M |
| Net Income | -$83.00M |
| EBITDA | -$22.35M |
| EBIT | -$26.34M |
| Reported EPS (TTM) | -$0.45 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $184.56M |
|---|---|
| Total Debt | $165.54M |
| Net Cash | $19.02M |
| Net Cash Per Share | $0.22 |
| Working Capital | $133.11M |
| Shareholder Equity | -$347.64M |
| Total Assets | $345.02M |
| Total Liabilities | $692.66M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $302.00K of capital spending, operating cash flow left -$21.04M of free cash flow.
| Operating Cash Flow | -$20.74M |
|---|---|
| Capital Expenditures | $302.00K |
| Free Cash Flow | -$21.04M |
| FCF Per Share | -$0.26 |
| Depreciation and Amortization | $3.99M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -9.26%.
| Gross Margin | 80.68% |
|---|---|
| Operating Margin | -9.26% |
| Pretax Margin | -30.19% |
| Net Margin | -30.19% |
| EBITDA Margin | -8.13% |
| EBIT Margin | -9.58% |
| FCF Margin | -7.65% |
Dividends and Yields
PHAT does not pay a dividend. Its free cash flow yield is -4.51%.
| FCF Yield | -4.51% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 7 similar companies, PHAT has the 6th highest P/S.
P/S RatioPeer median 7.2x
ROICPeer median -32.76%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -69.50%
| P/S Ratio | 1.7x vs 7.2x median |
|---|---|
| ROIC | 11.43% vs -32.76% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +86.75% vs -69.50% median |
Analyst Forecast
Consensus estimates put revenue growth at 66.94% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +66.94% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PHAT
What is PHAT's market cap?
Phathom Pharmaceuticals has a market cap of $477.99M. Its enterprise value, which adds debt and subtracts cash, is $458.98M.
How many shares of PHAT are outstanding?
Phathom Pharmaceuticals has 84.89M shares outstanding. The count is up 15.66% from a year earlier.
Does PHAT pay a dividend?
No. Phathom Pharmaceuticals does not pay a dividend.
How much debt does PHAT have?
Phathom Pharmaceuticals has $165.54M of total debt and $184.56M of cash and equivalents, a net cash position of $19.02M.
PHAT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors